Search Results - "РАССТРОЙСТВА ШИЗОФРЕНИЧЕСКОГО СПЕКТРА"

1

Academic Journal

Персонализированная модель психосоциальной реабилитации пациентов с первым психотическим эпизодом: от симптоматической ремиссии к личностному восстановлению

Subject Terms: personal and social recovery, sociotherapeutic rehabilitation, schizophrenia spectrum disorders, личностно-социальное восстановление, психосоциальная реабилитация, first psychotic episode, реабилитация, psychosocial rehabilitation, первый психотический эпизод, расстройства шизофренического спектра

2

Review

Персонализированная модель психосоциальной реабилитации пациентов с первым психотическим эпизодом: от симптоматической ремиссии к личностному восстановлению

Subject Terms: personal and social recovery, sociotherapeutic rehabilitation, schizophrenia spectrum disorders, личностно-социальное восстановление, психосоциальная реабилитация, first psychotic episode, реабилитация, psychosocial rehabilitation, первый психотический эпизод, расстройства шизофренического спектра

3

Academic Journal

Gender nonconformity as a problem of mentalization ; Гендерная неконформность как проблема ментализации

Authors: K. S. Vinogradova, К. С. Виноградова

Source: Medical Herald of the South of Russia; Том 13, № 3 (2022); 7-12 ; Медицинский вестник Юга России; Том 13, № 3 (2022); 7-12 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2022-13-3

Subject Terms: расстройства шизофренического спектра, gender identity, gender dysphoria, gender incongruence, mentalization, schizophrenia spectrum disorders, гендерная идентичность, гендерная дисфория, гендерное несоответствие, ментализация

File Description: application/pdf

Relation: https://www.medicalherald.ru/jour/article/view/1533/903; Менделевич В.Д. Почему транссексуализм не является психическим расстройством, или как сделать психиатрическую классификацию научной. Неврологический вестник. 2018;50(3):5-10. DOI:10.17816/nb14115; Littman L. Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria. PLoS One. 2018;13(8):e0202330. DOI:10.1371/journal.pone.0202330. Erratum in: PLoS One. 201914(3):e0214157.; Дьяченко А. В., Солдаткин В. А., Бухановская О. А., Переход А. Я. Расстройства половой идентификации у детей и подростков в психиатрической практике. Социальная и клиническая психиатрия. 2021;31(2):69-78. eLIBRARY ID: 46413359; Bewley S, Clifford D, McCartney M, Byng R. Gender incongruence in children, adolescents, and adults. Br J Gen Pract. 2019;69(681):170-171. DOI:10.3399/bjgp19X701909.; de Graaf NM, Giovanardi G, Zitz C, Carmichael P. Sex Ratio in Children and Adolescents Referred to the Gender Identity Development Service in the UK (2009-2016). Arch Sex Behav. 2018;47(5):1301-1304. DOI:10.1007/s10508-018-1204-9.; Kaltiala-Heino R, Bergman H, Tyolajarvi M, Frisen L. Gender dysphoria in adolescence: current perspectives. Adolesc Health Med Th er. 2018;9:31-41. DOI:10.2147/AHMT.S135432.; Zucker K.J. The myth of persistence: Response to “A criti- 7. cal commentary on follow-up studies and ‘desistance' theories about transgender and gender non-conforming children” by Temple Newhook et al. International Journal of Transgenderism. 2018;19(2):231-245. DOI:10.1080/15532739.2018.1468293; D'Angelo R, Syrulnik E, Ayad S, Marchiano L, Kenny 8. DT, Clarke P. One Size Does Not Fit All: In Support of Psychotherapy for Gender Dysphoria. Arch Sex Behav. 2021;50(1):7-16. DOI:10.1007/s10508-020-01844-2.; Turban JL, Beckwith N, Reisner SL, Keuroghlian AS. As- 9. sociation Between Recalled Exposure to Gender Identity Conversion Efforts and Psychological Distress and Suicide Attempts Among Transgender Adults. JAMA Psychiatry. 2020;77(1):68-76. DOI:10.1001/jamapsychiatry.2019.2285.; Furlong Y, Janca A. Epidemiology of personality disorders 10. in individuals with gender dysphoria. Curr Opin Psychiatry. 2022;35(1):78-82. DOI:10.1097/YCO.0000000000000757.; Perrotta G. Etiological factors and comorbidities associated 11. with the “Gender Dysphoria”: Definition, clinical contexts, differential diagnosis and clinical treatments. Int J Sex Reprod Health Care. 2021;4(1):001-005. DOI:10.17352/ijsrhc.000018; Rajkumar RP. Gender identity disorder and schizophrenia: 12. neurodevelopmental disorders with common causal mechanisms? Schizophr Res Treatment. 2014;2014:463757. DOI:10.1155/2014/463757.; Дьяченко А.В., Бухановская О.А., Солдаткин В.А., 13. Перехов А.Я. Кто обращается к психиатру с запросом на изменение пола: результаты 30-летнего исследования. Психиатрия. 2020;18(3):32-41. DOI:10.30629/2618-6667-2020-18-3-32-41; Warrier V, Greenberg DM, Weir E, Buckingham C, Smith P, 14. et al. Elevated rates of autism, other neurodevelopmental and psychiatric diagnoses, and autistic traits in transgender and gender-diverse individuals. Nat Commun. 2020;11(1):3959. DOI:10.1038/s41467-020-17794-1.; Van Der Miesen AI, Hurley H, De Vries AL. Gen- 15. der dysphoria and autism spectrum disorder: A narrative review. Int Rev Psychiatry. 2016;28(1):70-80. DOI:10.3109/09540261.2015.1111199.; Glidden D, Bouman WP, Jones BA, Arcelus J. Gender 16. Dysphoria and Autism Spectrum Disorder: A Systematic Review of the Literature. Sex Med Rev. 2016;4(1):3-14. DOI:10.1016/j.sxmr.2015.10.003.; Kallitsounaki A, Williams D. Mentalising Moderates the 17. Link between Autism Traits and Current Gender Dysphoric Features in Primarily Non-autistic, Cisgender Individuals. J Autism Dev Disord. 2020;50(11):4148-4157. DOI:10.1007/s10803-020-04478-4.; Zupanic S, Kruljac I, Sostaric Zvonar M, Drobnic Radobul- 18. jac M. Case Report: Adolescent With Autism and Gender Dysphoria. Front Psychiatry. 2021;12:671448. DOI:10.3389/fpsyt.2021.671448.; Kallitsounaki A, Williams DM, Lind SE. Links Between 19. Autistic Traits, Feelings of Gender Dysphoria, and Mentalising Ability: Replication and Extension of Previous Findings from the General Population. J Autism Dev Disord. 2021;51(5):1458-1465. DOI:10.1007/s10803-020-04626-w.; Lingiardi V, McWilliams N. The psychodynamic diagnostic manual - 2nd edition (PDM-2). World Psychiatry. 2015;14(2):237-9. DOI:10.1002/wps.20233.; Fonagy, P, Gergely, G., Jurist, E.L., Target, M. Affect regulation, mentalization and the development of the self. New York: Other Press; 2002.; Соколова Е.Т. Нарушения ментализации в клинической и культурной парадигме Л.С. Выготского. Психологические исследования. 2017;10(56). DOI:10.54359/ps.v10i56.343; Fonagy Р, Bateman A. The development of borderline personality disorder- a mentalizing model. Journal of Personality Disorders. 2008;22(1):4-21. DOI:10.1521/pedi.2008.22.1.4; Лэйнг Р. Д. Расколотое «Я»: пер. с англ. Спб.; 1995; Соколова Е.Т., Андреюк К.О. Особенности ментализации у пациентов с шизотипическими расстройствами. Психологические исследования. 2016;9(46). DOI:10.54359/ps.v9i46.485; Ball Cooper E, Anderson JL, Sharp C, Langley HA, Venta A. Attachment, Mentalization, and Criterion B of the Alternative DSM-5 Model for Personality Disorders (AMPD). Borderline Personal Disord Emot Dysregul. 2021;8(1):23. DOI:10.1186/s40479-021-00163-9.; https://www.medicalherald.ru/jour/article/view/1533

Availability: https://www.medicalherald.ru/jour/article/view/1533
https://doi.org/10.21886/2219-8075-2022-13-3-7-12

View record from BASE

4

Academic Journal

«Золотой выстрел» в лечении и диагностике шизофрении: психиатры или нейробиологи? ; “Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?

Authors: Дубатова Ирина Владимировна, Irina V. Dubatova, Анцыборов Лёма Андреевич, Lema A. Antsyborov, Хейгетян Артур Федорович, Artur F. Kheigetian, Анцыборов Андрей Викторович, Andrey V. Antsyborov

Contributors: Исследование не имело финансовой поддержки

Source: Interactive science; № 10(65); 9-24 ; Интерактивная наука; № 10(65); 9-24 ; ISSN: 2414-9411 ; 2414-9411 ; ISSN(electronic Version): 2500-2686 ; 2500-2686

Subject Terms: дофамин, schizophrenic spectrum disorders, polypharmacy, monotherapy, dopamine, glutamate, serotonin, antipsychotics, расстройства шизофренического спектра, полифармация, монотерапия, глутамат, серотонин, антипсихотические препараты

File Description: text/html

Relation: info:eu-repo/semantics/altIdentifier/pissn/2414-9411; info:eu-repo/semantics/altIdentifier/eissn/2500-2686; Monthly international scientific journal Interactive science Issue 10(65); https://interactive-plus.ru/e-articles/797/Action797-555399.pdf; Kondej M., Stępnicki P., Kaczor A. A. Multi-target approach for drug discovery against schizophrenia //International journal of molecular sciences. – 2018. -Vol. 19. – №. 10. -p. 3105; Alberca L. N., Talevi A. The Efficiency of Multi-target Drugs: A Network Approach //Approaching Complex Diseases. – 2020. -Vol. 3. -p. 63; Potkin S. G. et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research //NPJ schizophrenia. – 2020. -Vol. 6. – №. 1. -p. 1–10; Campana M. et al. Characteristics and definitions of ultra-treatment-resistant schizophrenia-A systematic review and meta-analysis //Schizophrenia Research. – 2021. -Vol. 228. -p. 218–226; Mørup M. F., Kymes S. M., Oudin Åström D. A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States //PloS one. – 2020. -Vol. 15. – №. 6. -p. e0234121; Marques T. R. et al. Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study //Psychopharmacology. – 2021. -p. 1–7; Huefner J. C. et al. Patterns of psychotropic medication at admission for youth in residential care //Journal of Child and Family Studies. – 2017. – Vol. 26. – №. 1. -p. 317–328.; Turabian J. L. Polypharmacy is an indicator of bad practice and low quality in general medicine //J Qual Healthcare Eco. – 2019. -Vol. 2. – №. 4. -; Lähteenvuo M., Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations //Drugs. – 2021. – Vol. 81. – №. 11. -p. 1273–1284; Chávez-Castillo M. et al. Depression as a neuroendocrine disorder: emerging neuropsychopharmacological approaches beyond monoamines //Advances in pharmacological sciences. – 2019. -Vol. 2019; Mishra R. K., Mishra A., Gupta A. Magic Shotgun Nature with Scattergun Approach of Curcumin Repurposing in Obsessive-compulsive disorder: A Novel Metaphysician of Drug Discovery //CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). – 2021; Stępnicki P. et al. Multi-targeted drug design strategies for the treatment of schizophrenia //Expert Opinion on Drug Discovery. – 2021. -Vol. 16. – №. 1. -p. 101–114; Saenz-Méndez P., Eriksson L. A. Exploring polypharmacology in drug design //Rational Drug Design. – Humana Press, New York, NY, 2018. -p. 229–243; Meltzer H. Y., Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs //Focus. – 2021. -Vol. 19. – №. 1. -p. 3–13; Tiihonen J. et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia //JAMA psychiatry. – 2019. -Vol. 76. – №. 5. -p. 499–507; Galling B. et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis //World Psychiatry. – 2017. -Vol. 16. – №. 1. -p. 77–89; Mentzel T. Q. et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis //The Journal of clinical psychiatry. – 2018. -Vol. 79. – №. 6. -p. 0–0; Luo C. et al. Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated with Clozapine or Risperidone and Those Never Treated //International Journal of Neuropsychopharmacology. – 2020. -Vol. 23. – №. 12. -p. 799–810.; Limandri B. J. Clinical use of dopamine modulators as third-generation antipsychotic agents //Journal of psychosocial nursing and mental health services. – 2019. -Vol. 57. – №. 2. -p. 7–11; Orsolini L., De Berardis D., Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics //Expert Opinion on Drug Safety. – 2020. -Vol. 19. – №. 8. -p. 981–998; Preda A., Shapiro B. B. A safety evaluation of aripiprazole in the treatment of schizophrenia //Expert Opinion on Drug Safety. – 2020. -Vol. 19. – №. 12. -p. 1529–1538; Fornaro M. et al. Brexpiprazole for treatment-resistant major depressive disorder //Expert opinion on pharmacotherapy. – 2019. -Vol. 20. – №. 16. -p. 1925–1933; Earley W. et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study //American Journal of Psychiatry. – 2019. -Vol. 176. – №. 6. -p. 439–448; Corponi F. et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone //European Neuropsychopharmacology. – 2019. -Vol. 29. – №. 9. -p. 971–985; Calabrese F. et al. The role of dopamine D3 receptors in the mechanism of action of cariprazine //CNS spectrums. – 2020. -Vol. 25. – №. 3. -p. 343–351; Duric V. et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model //International Journal of neuropsychopharmacology. – 2017. -Vol. 20. – №. 10. -p. 788–796.; Campbell R. H. et al. Review of cariprazine in management of psychiatric illness //Mental Health Clinician. – 2017. -Vol. 7. – №. 5. -p. 221–229; Garnock-Jones K. P. Cariprazine: a review in schizophrenia //CNS drugs. – 2017. -Vol. 31. – №. 6. -p. 513–525; Tarland E. et al. Effects of 2-bromoterguride, a dopamine D 2 receptor partial agonist, on cognitive dysfunction and social aversion in rats //Psychopharmacology. – 2018. -Vol. 235. – №. 1. -p. 99–108; Kang T. et al. Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements //Current Topics in Medicinal Chemistry. – 2021.; Wang S. M. et al. Investigational dopamine antagonists for the treatment of schizophrenia //Expert opinion on investigational drugs. – 2017. -Vol. 26. – №. 6. -p. 687–698.; Page C. E., Coutellier L. Reducing inhibition: A promising new strategy for the treatment of schizophrenia //EBioMedicine. – 2018. -Vol. 35. -p. 25; Kantrowitz J. T. Targeting Serotonin 5-HT 2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches //CNS drugs. – 2020. – p. 1–13; Vinkers C. H. Antipsychotics with no dopamine receptor blockade; promise or hype? //Nederlands tijdschrift voor geneeskunde. – 2020. -Vol. 164.; Morrison P. D., Murray R. M. The antipsychotic landscape: dopamine and beyond //Therapeutic advances in psychopharmacology. – 2018. -Vol. 8. – №. 4. -p. 127–135; Trabanco A. A., Bartolomé J. M., Cid J. M. mGluR2 positive allosteric modulators: an updated patent review (2013–2018) //Expert opinion on therapeutic patents. – 2019. -Vol. 29. – №. 7. -p. 497–507; Nicoletti F. et al. Targeting mGlu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia //Frontiers in psychiatry. – 2019. -Vol. 10. -p. 49; Stansley B. J., Conn P. J. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia //Current opinion in pharmacology. – 2018. -Vol. 38. -p. 31–36; Hellyer S. D. et al. Development of clickable photoaffinity ligands for metabotropic glutamate receptor 2 based on two positive allosteric modulators chemotypes //ACS chemical neuroscience. – 2020. -Vol. 11. – №. 11. -p. 1597–1609.; Marchi M. et al. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials //Expert Opinion on Drug Metabolism & Toxicology. – 2021. -Vol. 17. – №. 4. -p. 483–493; Koola M. M. Potential role of antipsychotic-galantamine-memantine combination in the treatment of positive, cognitive, and negative symptoms of schizophrenia //Molecular neuropsychiatry. – 2018. -Vol. 4. – №. 3. -p. 134–148; Wu Q., Huang J., Wu R. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia //Frontiers in Neuroscience. – 2021. -Vol. 15. -p. 362; Czobor P., Bitter I. Pharmacologic treatment of negative symptoms: focus on efficacy //Managing Negative Symptoms of Schizophrenia. – 2020. -p. 67; Aringhieri S. et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences //Pharmacology & Therapeutics. – 2018. -Vol. 192. -p. 20–41; MacKay M. A. B. et al. D-Serine: potential therapeutic agent and/or biomarker in schizophrenia and depression? //Frontiers in psychiatry. – 2019. -Vol. 10. -p. 25; Kumar A. et al. Potential drug targets and treatment of schizophrenia //Inflammopharmacology. – 2017. -Vol. 25. – №. 3. -p. 277–292; Yohn S. E., Conn P. J. Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia //Neuropharmacology. – 2018. -Vol. 136. -p. 438–448; Dean B., Scarr E. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia //Psychiatry research. – 2020. -Vol. 288. -p. 112989; Park R., Kim S., Kim E. Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia //Psychiatry investigation. – 2020. -Vol. 17. – №. 11. -p. 1158; Costa-Dookhan K. A. et al. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy //Expert opinion on drug safety. – 2020. -Vol. 19. – №. 1. -p. 43–57; Molins C. et al. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients //Psychiatry research. – 2017. -Vol. 258. -p. 153–157; Augustin M. et al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations //Schizophrenia research. – 2019. -Vol. 210. -p. 143–148; Edinoff A. N. et al. Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations //Neurology International. – 2021. -Vol. 13. – №. 3. -p. 445–463; Smith R. L. et al. Correlation between serum concentrations of N-desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study //CNS drugs. – 2017. -Vol. 31. – №. 11. -p. 991–997; Nichols J. H. Neuroleptics //Principles of Forensic Toxicology. – Springer, Cham, 2020. -p. 511–522; Frampton J. E. Brexpiprazole: a review in schizophrenia //Drugs. – 2019. -Vol. 79. – №. 2. -p. 189–200; Fukuyama K., Okada M. Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43 //International Journal of Molecular Sciences. – 2021. -Vol. 22. – №. 11. -p. 5623; Frankel J. S., Schwartz T. L. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole //Therapeutic advances in psychopharmacology. – 2017. -Vol. 7. – №. 1. -p. 29–41; Stummer L., Markovic M., Maroney M. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer’s disease //Neurodegenerative Disease Management. – 2020. -Vol. 10. – №. 4. -p. 205–217; Kaar S. J. et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology //Neuropharmacology. – 2020. -Vol. 172. -p. 107704; Mobed A. et al. Bioassay: A novel approach in antipsychotic pharmacology //Clinica Chimica Acta. – 2020. -Vol. 509. -p. 30–35; Ballard C. et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study //The Lancet Neurology. – 2018. -Vol. 17. – №. 3. -p. 213–222; Yunusa I., El Helou M. L., Alsahali S. Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-related psychosis //Frontiers in pharmacology. – 2020. -Vol. 11. -p. 87; Odland A. U., Kristensen J. L., Andreasen J. T. Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice //Behavioural Brain Research. – 2021. -Vol. 401. -p. 113093; Nebuka M. et al. Behavioral characteristics of 5-HT2C receptor knockout mice: Locomotor activity, anxiety-, and fear memory-related behaviors //Behavioural brain research. – 2020. -Vol. 379. -p. 112394; Hrnjadovic A. et al. Effect of a 5-HT7 Receptor Antagonist on Reversal Learning in the Rat Attentional Set-Shifting Test //ACS Chemical Neuroscience. – 2020. -Vol. 12. – №. 1. -p. 42–48; Hopkins S. C. et al. Discovery of Non-racemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders //Clinical Pharmacology & Therapeutics. – 2021; Castberg I. et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine //Acta Psychiatrica Scandinavica. – 2017. -Vol. 136. – №. 5. -p. 455–464; Asenjo-Lobos C. et al. Clozapine versus risperidone for people with schizophrenia //The Cochrane Database of Systematic Reviews. – 2018. -Vol. 2018. – №. 12; Olotu U. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. – 2017; Patrichi B. et al. Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study //Experimental and Therapeutic Medicine. – 2021. -Vol. 22. – №. 5. -p. 1–6; Delgado A. et al. Clozapine in bipolar disorder: A systematic review and meta-analysis //Journal of psychiatric research. – 2020. -Vol. 125. -p. 21–27; Bioque M. et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study //European Psychiatry. – 2020. – Т. 63. – №. 1.; Lähteenvuo M., Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations //Drugs. – 2021. -Vol. 81. – №. 11. -p. 1273–1284; Meftah A. M. et al. New discoveries for an old drug: a review of recent olanzapine research //Postgraduate medicine. – 2020. -Vol. 132. – №. 1. – p. 80–90; Yang L., Qi X. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function //Pakistan Journal of Medical Sciences. – 2021. -Vol. 37. – №. 3. -p. 646; Wang N. et al. Paroxetine combined with olanzapine in the treatment of schizophrenia //Pakistan journal of medical sciences. – 2020. -Vol. 36. – №. 3. -p. 516; Smith R. L. et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs-A study based on blood sample analyses from 24,239 patients //European Neuropsychopharmacology. – 2020. -Vol. 37. -p. 64–69; Lin S. K. Antipsychotic Polypharmacy: A dirty little secret or a fashion? //International Journal of Neuropsychopharmacology. – 2020. -Vol. 23. – №. 2. -p. 125–131; Jovanović M., Vučićević K., Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics-focus on clozapine, olanzapine and aripiprazole population models //Drug metabolism reviews. – 2020. -Vol. 52. – №. 1. -p. 1–18; Baandrup L. Polypharmacy in schizophrenia //Basic & clinical pharmacology & toxicology. – 2020. -Vol. 126. – №. 3. -p. 183–192; Foster A., King J. Antipsychotic polypharmacy //Focus. – 2020. -Vol. 18. – №. 4. -p. 375–385; Naguy A., Al-Enezi N. Lamotrigine uses in psychiatric practice //American journal of therapeutics. – 2019. -Vol. 26. – №. 1. -p. e96-e102; Douglas-Hall P. et al. Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust //Therapeutic advances in psychopharmacology. – 2017. -Vol. 7. – №. 1. -p. 17–24; Crawford M. J. et al. Lamotrigine for people with borderline personality disorder: a RCT //Health Technology Assessment (Winchester, England). – 2018. -Vol. 22. – №. 17. -p. 1–68; Zheng W. et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials //The Journal of clinical psychiatry. – 2017. -Vol. 78. – №. 5. -p. 0–0.; Lee E. E. et al. Late-onset schizophrenia. – 2020; Talbot P. S. Anticonvulsants 12 Chapter for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine //Seminars in Clinical Psychopharmacology. – Cambridge University Press, 2020. -p. 362.; Khandelwal A., Mahajan C., Prabhakar H. Anti-epileptic Drugs (AEDs) //Pharmacology in Clinical Neurosciences. – Springer, Singapore, 2020. – p. 173–256; Goud Alladi C. et al. DNA methylation as a biomarker of treatment response variability in serious mental illnesses: a systematic review focused on bipolar disorder, schizophrenia, and major depressive disorder //International journal of molecular sciences. – 2018. -Vol. 19. – №. 10. -p. 3026.; Grover S., Sahoo S. Treatment of clozapine nonresponders //Current Treatment Options in Psychiatry. – 2019. -Vol. 6. – №. 1. -p. 32–63; Maan J. S., TvH D., Saadabadi A. Carbamazepine. – 2018; Okuma T. The discovery of the psychotropic effects of carbamazepine //The Psychopharmacologists III. – CRC Press, 2020. -p. 259–280; Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management //World Journal of Psychiatry. – 2021. -Vol. 11. – №. 8. -p. 429; Carboni L. et al. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies //Translational psychiatry. – 2019. -Vol. 9. – №. 1. -p. 1–12; Kaur H. et al. Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naïve patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns? //Journal of Mental Health and Human Behaviour. – 2019. -Vol. 24. – №. 1. -p. 15; Gregory A., Mallikarjun P., Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta-analysis //The British Journal of Psychiatry. – 2017. -Vol. 211. – №. 4. -p. 198–204; Bittner R. A. et al. Recent Developments in Treating Cognitive Impairment Associated with Schizophrenia. – 2021; Jones M. T., Strassnig M. T., Harvey P. D. Emerging 5-HT receptor antagonists for the treatment of Schizophrenia //Expert opinion on emerging drugs. – 2020. -Vol. 25. – №. 2. -p. 189–200; Căpățînă O. O., Micluția I. V., Fadgyas‑stănculete M. Current perspectives in treating negative symptoms of schizophrenia: A narrative review //Experimental and therapeutic medicine. – 2021. -Vol. 21. – №. 3. – p. 1–1; Yang A. C., Tsai S. J. New targets for schizophrenia treatment beyond the dopamine hypothesis //International journal of molecular sciences. – 2017. -Vol. 18. – №. 8. -p. 1689; Ng Q. X., Chong J. W. X., Chee K. T. Add-on pharmacotherapy for patients with first-episode schizophrenia: a clinical perspective //European Journal of Clinical Pharmacology. – 2021. -Vol. 77. – №. 6. -p. 931–932; Shafti S. S. Systematic Review of Local Studies Regarding Efficiency of Add-On Medications on Negative Symptoms of Schizophrenia: A Meta-Analysis //Current Psychopharmacology. – 2019. -Vol. 8. – №. 2. -p. 113–122.; Shafti S. S. Meta-analysis of Native Studies as Regards the Effectiveness of Antidepressants on Deficit Syndrome of Schizophrenia: A Systematic Review //Current Psychopharmacology. – 2017. -Vol. 6. – №. 2. – p. 148–157; Zaman H., Gibson R. C., Walcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses //Cochrane Database of Systematic Reviews. – 2019. – №. 8; Hsu W. Y., Lane H. Y., Lin C. H. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease //Frontiers in psychiatry. – 2018. -Vol. 9. -p. 91; Czarnecka K. et al. Memantine in neurological disorders-schizophrenia and depression //Journal of Molecular Medicine. – 2021. -p. 1–8; Martínez A. L. et al. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments //International Journal of Molecular Sciences. – 2021. -Vol. 22. – №. 18. -p. 9905; Guercio G. D. et al. Improving cognitive training for schizophrenia using neuroplasticity enhancers: lessons from decades of basic and clinical research //Schizophrenia research. – 2019. -Vol. 207. -p. 80–92; Sheerin Fathima A. S. Neurocognition and Disability in Patients with Schizophrenia compared with Healthy Controls: дис. – PSG Institute of Medical Science and Research, Coimbatore, 2019; Sinkeviciute I. et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis //NPJ schizophrenia. – 2018. -Vol. 4. – №. 1. -p. 1–14; Junho B. T., de Oliveira V. F. The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review //Archives of Clinical Psychiatry (São Paulo). – 2019. -Vol. 46. -p. 165–168; Zheng W. et al. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials //Schizophrenia research. – 2019. -Vol. 209. -p. 12–21; Koola M. M., Praharaj S. K., Pillai A. Galantamine-memantine combination as an antioxidant treatment for schizophrenia //Current behavioral neuroscience reports. – 2019. -Vol. 6. – №. 2. -p. 37–50; Iqbal M. N., Levin C. J., Levin F. R. Treatment for substance use disorder with co-occurring mental illness //FOCUS, A Journal of the American Psychiatric Association. – 2019. -Vol. 17. – №. 2. -p. 88–97; Li K. J., Chen A., DeLisi L. E. Opioid use and schizophrenia //Current opinion in psychiatry. – 2020. -Vol. 33. – №. 3. -p. 219–224; Bennett M. E., Bradshaw K. R., Catalano L. T. Treatment of substance use disorders in schizophrenia //The American journal of drug and alcohol abuse. – 2017. -Vol. 43. – №. 4. -p. 377–390; Pourshams M. et al. The Evaluation of Atypical Antipsychotic Augmentation with Atomoxetine in the Reduction of Negative Symptoms in Patients with Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Clinical Trial //Clinical Schizophrenia & Related Psychoses. – 2020. -Vol. 14. – №. 2. -p. 54–57; Robbins T. W. Pharmacological treatment of cognitive deficits in nondementing mental health disorders //Dialogues in clinical neuroscience. – 2019. -Vol. 21. – №. 3. -p. 301; Giakoumatos C. I., Osser D. The psychopharmacology algorithm project at the Harvard south shore program: an update on unipolar nonpsychotic depression //Harvard review of psychiatry. – 2019. -Vol. 27. – №. 1. -p. 33–52; Ciruela F. et al. The adenosinergic system in the neurobiology of schizophrenia: Prospective adenosine receptor-based pharmacotherapy //Psychiatry and Neuroscience Update-Vol. II. – Springer, Cham, 2017. -p. 405–419.; Beggiato S. et al. Adenosine and Kynurenic Acid Interactions: Possible Relevance for Schizophrenia Treatment? //Frontiers in Pharmacology. – 2021. -Vol. 12; Cheffer A. et al. Purinergic system in psychiatric diseases //Molecular psychiatry. – 2018. -Vol. 23. – №. 1. -p. 94–106; Gadelha A. et al. Is adenosine associated with sudden death in schizophrenia? A new framework linking the adenosine pathway to risk of sudden death //Neuroscience & Biobehavioral Reviews. – 2018. -Vol. 84. -p. 29–34; Behmanesh H. et al. Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial //Clinical neuropharmacology. – 2019. -Vol. 42. – №. 6. -p. 189–196; Lago S. G., Bahn S. Clinical trials and therapeutic rationale for drug repurposing in schizophrenia //ACS chemical neuroscience. – 2018. -Vol. 10. – №. 1. -p. 58–78; Deguil J., Bordet R. Contributions of animal models of cognitive disorders to neuropsychopharmacology //Therapies. – 2021. -Vol. 76. – №. 2. -p. 87–99; Lintunen J. et al. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia //NPJ schizophrenia. – 2021. -Vol. 7. – №. 1. -p. 1–7; Chen A. T., Malmstrom T., Nasrallah H. A. Allopurinol augmentation in acute mania: a meta-analysis of placebo-controlled trials //Journal of affective disorders. – 2018. -Vol. 226. -p. 245–250; Berry T., Abohamza E., Moustafa A. A. Treatment-resistant schizophrenia: Focus on the transsulfuration pathway //Reviews in the Neurosciences. – 2020. -Vol. 31. – №. 2. -p. 219–232; Shalbafan M. et al. The role of celecoxib in treatment of psychiatric disorders: A review article //J. Neurol. Psychol. – 2018. -Vol. 6. – №. 4; Kotecha A., Upthegrove R. Celecoxib plus standard care for people with schizophrenia //The Cochrane Database of Systematic Reviews. – 2018. -Vol. 2018. – №. 12.; Hong J., Bang M. Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing //Clinical Psychopharmacology and Neuroscience. – 2020. -Vol. 18. – №. 1. -p. 10; Cho M. et al. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials //Australian & New Zealand Journal of Psychiatry. – 2019. -Vol. 53. – №. 8. -p. 742–759; Fond G. et al. The role of inflammation in the treatment of schizophrenia //Frontiers in psychiatry. – 2020. -Vol. 11. -p. 160; Faridhosseini F. et al. Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial. – 2020; McGregor C., Riordan A., Thornton J. Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms //Frontiers in neuroendocrinology. – 2017. -Vol. 47. -p. 19–33; Brzezinski-Sinai N. A., Brzezinski A. Schizophrenia and sex hormones: what is the link? //Frontiers in Psychiatry. – 2020. -Vol. 11; Brand B. A., de Boer J. N., Sommer I. E. C. Estrogens in schizophrenia: progress, current challenges and opportunities //Current opinion in psychiatry. – 2021. -Vol. 34. – №. 3. -p. 228; de Boer J. et al. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis //npj Schizophrenia. – 2018. -Vol. 4. – №. 1. -p. 1–6; Fernando P., Sommer I. E. C., Hasan A. Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia? //Current opinion in psychiatry. – 2020. -Vol. 33. – №. 3. -p. 192–199; Riecher-Rössler A., Butler S., Kulkarni J. Sex and gender differences in schizophrenic psychoses-a critical review //Archives of women's mental health. – 2018. -Vol. 21. – №. 6. -p. 627–648; Searles S., Makarewicz J. A., Dumas J. A. The role of estradiol in schizophrenia diagnosis and symptoms in postmenopausal women //Schizophrenia research. – 2018. -Vol. 196. -p. 35–38; Lascurain M. B. et al. Improvement in depression with estrogen treatment in women with schizophrenia //Archives of women's mental health. – 2020. -Vol. 23. – №. 2. -p. 149–154; Lombardo G. et al. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis //Psychoneuroendocrinology. – 2019. -Vol. 110. -p. 104420; Soria V. et al. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis //Psychoneuroendocrinology. – 2018. -Vol. 93. -p. 8–19; Woldesenbet Y. M. et al. The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study //SAGE open medicine. – 2021. -Vol. 9. -p. 20503121211056216; Fujii Y. et al. Cushing's syndrome and psychosis: a case report and literature review //The primary care companion for CNS disorders. – 2018. -Vol. 20. – №. 5. -p. 0–0; Mikulska J. et al. HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation //Brain Sciences. – 2021. -Vol. 11. – №. 10. -p. 1298; Labad J. The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders //Psychoneuroendocrinology. – 2019. -Vol. 102. -p. 24–36; Yates C. et al. Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics //Current Treatment Options in Psychiatry. – 2021. -p. 1–29; Wagner E. et al. Clozapine augmentation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance //Journal of Psychopharmacology. – 2019. – Т. 33. – №. 4. – С. 423–435; Ceskova E., Silhan P. Novel treatment options in depression and psychosis //Neuropsychiatric disease and treatment. – 2018. -Vol. 14. -p. 741; Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses //Therapeutic advances in psychopharmacology. – 2018. -Vol. 8. – №. 11. -p. 303–318; Schwartz M. D. et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases //Expert opinion on therapeutic targets. – 2018. -Vol. 22. – №. 6. -p. 513–526; Dodd S. et al. Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry? //Neuroscience & Biobehavioral Reviews. – 2021. -Vol. 120. -p. 537–541; Girgis R. R. et al. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review //Journal of psychiatric research. – 2019. -Vol. 108. -p. 57–83; Kirkpatrick B., Kennedy B. K. Accelerated aging in schizophrenia and related disorders: Future research //Schizophrenia research. – 2018. -Vol. 196. -p. 4–8; Luykx J. J. et al. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine //The British Journal of Psychiatry. – 2020. -Vol. 217. – №. 3. -p. 498–505; Siskind D. J. et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis //Australian & New Zealand Journal of Psychiatry. – 2018. -Vol. 52. – №. 8. -p. 751–767; Harvey P. D., Sand M. Pharmacological augmentation of psychosocial and remediation training efforts in schizophrenia //Frontiers in psychiatry. – 2017. -Vol. 8. -p. 177; Galling B. et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia //Acta Psychiatrica Scandinavica. – 2018. -Vol. 137. – №. 3. -p. 187–205; Nimgaonkar V. L. et al. The complement system: a gateway to gene-environment interactions in schizophrenia pathogenesis //Molecular psychiatry. – 2017. -Vol. 22. – №. 11. -p. 1554–1561; Yu H. et al. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study //The Lancet Psychiatry. – 2018. -Vol. 5. – №. 4. -p. 327–338

Availability: https://interactive-plus.ru/files/Books/6204bd59475d0.jpeg?req=555399
https://interactive-plus.ru/article/555399/discussion_platform
https://doi.org/10.21661/r-555399

View record from BASE

5

Academic Journal